NCCN Guidelines Update Adds Momelotinib for High-, Low-Risk Myelofibrosis

Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia.

Related Keywords

,Women Health ,Digital Health ,Population Health ,Nccn Guideline Updates ,Momelotinib ,Jak Inhibitors ,Myelofibrosis ,Rare Diseases ,